CPhI Milan 2026 brought together the international pharmaceutical community, providing a key meeting point for industry professionals, experts and decisionmakers from across the global pharmaceutical value chain. With its broad international reach, the event offered an excellent opportunity to exchange ideas, discuss industry developments and build new connections. Our team was pleased to be part of this important industry gathering, meeting customers and partners and showcasing its expertise in pharmaceutical drug delivery.
CPHI is one of the leading international events for the pharmaceutical industry, bringing together over 2.900 companies and over 62.000 experts from across the pharmaceutical value chain. For AdhexPharma, participating in CPHI has become an important opportunity to strengthen existing relationships, establish new connections and exchange ideas with industry professionals.
This year, AdhexPharma welcomed visitors to one of its largest booths to date, bringing together a team of 19 colleagues from different departments. The event was a great opportunity to demonstrate the collaborative spirit behind AdhexPharma's work and to engage with visitors about their projects, challenges and ideas for future pharmaceutical products.
One of the highlights of this year's participation was AdhexPharma's Paper Feasibility Study prize draw. Visitors had the opportunity to enter a draw to win a paper feasibility study exploring whether their product concept or active pharmaceutical ingredient (API) could be suitable for one of AdhexPharma's drug delivery technologies.
The winning participant will have the opportunity to explore the feasibility of their concept across AdhexPharma's technology platforms: Mucofilm®, Rapidfilm®, Transfilm® and Impregnated Matrix Patch. The study will provide an initial assessment of the concept and help determine whether it could be a promising candidate for further development.
We look forward to seeing what the feasibility study reveals. Every new pharmaceutical product starts with an idea, and exploring alternative dosage forms can open up new possibilities for drug delivery.
Beyond the meetings and networking opportunities, CPHI Milan provided valuable insights into current interests and emerging opportunities across the pharmaceutical industry. Several topics stood out in our conversations.
Oral films and transdermal patches attracted interest as alternative dosage forms and potential additions to existing product portfolios. For pharmaceutical companies, these technologies can offer opportunities for lifecycle management, line extensions and the exploration of new drug delivery approaches.
Additionally, patient needs remain an important consideration in pharmaceutical development. Exploring alternatives to conventional dosage forms, such as oral films and transdermal patches, can open up new possibilities for drug administration and product differentiation. For pharmaceutical companies, selecting the right drug delivery approach means considering not only the active ingredient, but also the intended application, patient needs and product requirements.
Women's health also emerged as a topic of interest in our discussions. Innovative dosage forms and drug delivery technologies may offer opportunities to address specific product development needs in this field, depending on the active ingredient, target application and patient requirements.
Above all, the conversations in Milan reinforced the importance of direct exchange between pharmaceutical companies, technology providers and development specialists. Understanding specific project requirements at an early stage can help identify potential opportunities and determine the most appropriate direction for further development.
Sustainability continues to feature in discussions about the future of pharmaceutical development and manufacturing. As the industry explores new technologies and product concepts, environmental considerations are becoming an increasingly relevant part of the broader conversation. The challenge is to identify solutions that balance sustainability objectives with product quality, safety and technical feasibility.
For AdhexPharma, CPHI Milan 2026 was more than an opportunity to showcase its technologies. It was a chance to connect with pharmaceutical companies, better understand their development challenges and explore how innovative drug delivery solutions could support their projects.
The conversations and connections made during the event provide a valuable starting point for continued collaboration. By working closely with pharmaceutical partners and assessing the specific requirements of each project, AdhexPharma aims to help identify suitable technologies and explore new opportunities for pharmaceutical product development.
We would like to thank everyone who visited our booth, shared their ideas and took the time to connect with our team in Milan. We look forward to continuing these conversations and exploring what we can achieve together.
See you at the next CPhI in Frankfurt in 2027! And if you want to meet us at another event before, you can find a list of our next one here: AdhexPharma events.